Patents by Inventor Aaron Yamniuk

Aaron Yamniuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11795231
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: October 24, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • Publication number: 20230322941
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: March 10, 2023
    Publication date: October 12, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Suzanne J. Suchard
  • Patent number: 11773178
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: October 3, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • Publication number: 20230203177
    Abstract: The disclosure provides variants of an antibody wherein the variant antibodies have modified net charge properties relative to the corresponding unmodified antibody. Certain variants have improved pharmacokinetic properties relative to the corresponding unmodified antibody. Certain antibody variants bind CD40. Compositions and methods of use of the same are also provided.
    Type: Application
    Filed: May 17, 2021
    Publication date: June 29, 2023
    Inventors: Aaron Yamniuk, Mary Struthers
  • Patent number: 11613585
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: March 28, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Suzanne J. Suchard
  • Publication number: 20220177596
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: December 23, 2021
    Publication date: June 9, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Suzanne J. SUCHARD
  • Publication number: 20220169742
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 2, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, Jr., Akbar NAYEEM, Ginger RAKESTRAW
  • Publication number: 20220153856
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Publication number: 20220144962
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 12, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Publication number: 20220073636
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: November 9, 2021
    Publication date: March 10, 2022
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
  • Patent number: 11261258
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: March 1, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • Patent number: 11254750
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: February 22, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • Patent number: 11220550
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: January 11, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Suzanne J. Suchard
  • Patent number: 11180567
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 23, 2021
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Patent number: 11136406
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: October 5, 2021
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
  • Publication number: 20210054090
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 25, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Publication number: 20200199244
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Inventors: Anish SURI, Steven SHERIFF, Suzanne SUCHARD, Aaron YAMNIUK, Stanley KRYSTEK, James TAMURA, James BRYSON, Steven GRANT, Philip DREW
  • Publication number: 20200157233
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: November 18, 2019
    Publication date: May 21, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Publication number: 20200148779
    Abstract: Modified IgG1 Fc domains having reduced binding to Fc-gamma-receptors are provided. Further provided are fusion polypeptides comprising a modified IgG1 Fc domain. An antibody polypeptide that specifically binds a human CD40 is provided, wherein the antibody polypeptides are fusions of a domain antibody (dAb) comprising a single VH domain and an Fc domain. The antibody polypeptides do not exhibit CD40 agonist activity, do not substantially activate immature dendritic cells, and have improved biophysical properties.
    Type: Application
    Filed: May 24, 2018
    Publication date: May 14, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Suzanne J. SUCHARD
  • Patent number: 10544228
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: January 28, 2020
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew